Services
Chemistry, Manufacturing, & Controls (CMC) changes
Strategic CMC frameworks for peptides and biotherapeutcis, including oncolytic viruses and cell&gene therapy products, grounded on Quality by Design (ICH Q8/Q9/Q10/Q14) and aligned with regulatory expectations across the product lifecycle.
LAIZ integrates manufacturing science, analytical strategy, and regulatory insight to ensure consistent product quality, support comparability assessments, and anticipate clinical implications of critical quality attribute (CQA) changes — including potential impact on immunogenicity and clinical performance.
We define proactive CMC regulatory strategies that anticipate approval challenges, minimize commercialization delays, and mitigate the risk of supply disruptions.
Our approach includes:
In-depth gap analysis of comparability protocols
Evaluation of quality control (QC) method performance during technology transfer
Assessment of clinical consequences associated with CQA changes affecting safety, exposure, or efficacy
Preparation for regulatory interactions across development stages (EMA & FDA)
Regulatory strategy
We integrate product and process knowledge to predict clinical risks associated with manufacturing changes. By linking CQAs to safety, pharmacokinetics, exposure, and biological activity, we ensure manufacturing decisions are scientifically justified and regulator-ready.
This integrated assessment is particularly critical for complex biologics and advanced therapy medicinal products (ATMPs).
Integration of Data
Manufacturing process parameters and CQAs are evaluated alongside in vitro biological activity and pharmacokinetic considerations to determine whether additional preclinical or clinical evidence is required.
This translational perspective ensures that CMC decisions are aligned with clinical relevance and long-term regulatory expectations.
Translational approach
Risk prioritization
Post-translational modifications, product variants, and process-related impurities are systematically assessed to prioritize risks and avoid unnecessary clinical burden.
We apply structured risk frameworks to ensure that development resources are focused on attributes with meaningful impact on product quality, immunogenicity, and patient safety.